MIB guides: [⁸⁹Zr]Zr-DFO-trastuzumab and [⁶⁴Cu]Cu-NOTA-Trastuzumab for Preclinical Cancer Imaging.

IF 2.5 4区医学 Q2 RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING

Molecular Imaging and Biology Pub Date : 2025-06-26 DOI:10.1007/s11307-025-02022-3

Cristina Simó, Alexander C Vanover, E Carmen Azevedo, Patrícia M R Pereira

{"title":"MIB guides: [89Zr]Zr-DFO-trastuzumab and [64Cu]Cu-NOTA-Trastuzumab for Preclinical Cancer Imaging.","authors":"Cristina Simó, Alexander C Vanover, E Carmen Azevedo, Patrícia M R Pereira","doi":"10.1007/s11307-025-02022-3","DOIUrl":null,"url":null,"abstract":"Radiopharmaceuticals based on antibody biomolecules are widely used in oncology for positron emission tomography (PET). Trastuzumab, an antibody that targets the epidermal growth factor receptor 2 (HER2), has been extensively studied for both preclinical and clinical cancer imaging. This MIB guide specifically focuses on the radiolabeling of the antibody trastuzumab with zirconium-89 (89Zr) and copper-64 (64Cu) for PET imaging. The guide describes the steps for conjugating trastuzumab with p-SCN-Bn-deferoxamine (DFO) or 2,2',2''-(1,4,7-triazacyclononane-1,4,7-triyl)triacetic acid (p-SCN-Bn-NOTA) chelators through conjugation between the isothiocyanate (-SCN) functional group on the chelator with lysines on the trastuzumab. We also describe subsequent radiolabeling steps with 89Zr or 64Cu. The steps described here can be adapted to the radiolabeling of other antibodies upon protocol optimization.","PeriodicalId":18760,"journal":{"name":"Molecular Imaging and Biology","volume":" ","pages":""},"PeriodicalIF":2.5000,"publicationDate":"2025-06-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12311990/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Molecular Imaging and Biology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s11307-025-02022-3","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING","Score":null,"Total":0}

引用次数: 0

Abstract

Radiopharmaceuticals based on antibody biomolecules are widely used in oncology for positron emission tomography (PET). Trastuzumab, an antibody that targets the epidermal growth factor receptor 2 (HER2), has been extensively studied for both preclinical and clinical cancer imaging. This MIB guide specifically focuses on the radiolabeling of the antibody trastuzumab with zirconium-89 (⁸⁹Zr) and copper-64 (⁶⁴Cu) for PET imaging. The guide describes the steps for conjugating trastuzumab with p-SCN-Bn-deferoxamine (DFO) or 2,2',2''-(1,4,7-triazacyclononane-1,4,7-triyl)triacetic acid (p-SCN-Bn-NOTA) chelators through conjugation between the isothiocyanate (-SCN) functional group on the chelator with lysines on the trastuzumab. We also describe subsequent radiolabeling steps with ⁸⁹Zr or ⁶⁴Cu. The steps described here can be adapted to the radiolabeling of other antibodies upon protocol optimization.

查看原文本刊更多论文

MIB指南：[89Zr] zr - dfo -曲妥珠单抗和[64Cu] cu - nota -曲妥珠单抗用于临床前癌症成像。

基于抗体生物分子的放射性药物广泛应用于肿瘤学正电子发射断层扫描（PET）。曲妥珠单抗是一种靶向表皮生长因子受体2 （HER2）的抗体，已被广泛研究用于临床前和临床癌症成像。本MIB指南特别侧重于用锆-89 （89Zr）和铜-64 （64Cu）对抗体曲妥珠单抗进行PET成像的放射性标记。该指南描述了曲妥珠单抗与p- scn - bn -去铁胺（DFO）或2,2',2 " -（1,4,7-三氮环壬烷-1,4,7-三基）三乙酸（p- scn - nota）螯合剂结合的步骤，通过螯合剂上的异硫氰酸（- scn）官能团与曲妥珠单抗上的赖氨酸之间的结合。我们还描述了随后用89Zr或64Cu进行放射性标记的步骤。这里描述的步骤可以适用于方案优化后的其他抗体的放射性标记。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Molecular Imaging and Biology 医学-核医学

CiteScore

6.90

自引率

3.20%

发文量

审稿时长

3 months

期刊介绍： Molecular Imaging and Biology (MIB) invites original contributions (research articles, review articles, commentaries, etc.) on the utilization of molecular imaging (i.e., nuclear imaging, optical imaging, autoradiography and pathology, MRI, MPI, ultrasound imaging, radiomics/genomics etc.) to investigate questions related to biology and health. The objective of MIB is to provide a forum to the discovery of molecular mechanisms of disease through the use of imaging techniques. We aim to investigate the biological nature of disease in patients and establish new molecular imaging diagnostic and therapy procedures. Some areas that are covered are: Preclinical and clinical imaging of macromolecular targets (e.g., genes, receptors, enzymes) involved in significant biological processes. The design, characterization, and study of new molecular imaging probes and contrast agents for the functional interrogation of macromolecular targets. Development and evaluation of imaging systems including instrumentation, image reconstruction algorithms, image analysis, and display. Development of molecular assay approaches leading to quantification of the biological information obtained in molecular imaging. Study of in vivo animal models of disease for the development of new molecular diagnostics and therapeutics. Extension of in vitro and in vivo discoveries using disease models, into well designed clinical research investigations. Clinical molecular imaging involving clinical investigations, clinical trials and medical management or cost-effectiveness studies.